Evaxion Biotech AS (EVAX)
3.75
-0.16
(-4.09%)
USD |
NASDAQ |
May 07, 16:00
3.75
0.00 (0.00%)
After-Hours: 16:27
Evaxion Biotech Revenue (Quarterly): 0.073M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 0.073M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.073M
Minimum
Dec 2023
0.073M
Maximum
Dec 2023
0.073M
Average
0.073M
Median
Dec 2023
Revenue (Quarterly) Benchmarks
DBV Technologies SA | -- |
Ascendis Pharma A/S | 104.16M |
Cellectis SA | 0.283M |
Adaptimmune Therapeutics PLC | 0.231M |
Akari Therapeutics PLC | -- |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -4.523M |
Total Expenses (Quarterly) | 4.437M |
EPS Diluted (Quarterly) | -1.50 |
Enterprise Value | 23.46M |
Profit Margin (Quarterly) | -6.20K% |
Earnings Yield | -216.0% |